This is an AI translated post.
Select Language
Summarized by durumis AI
- Cellontec is pursuing entry into the Chinese medical beauty market through its bio-collagen business, and the Gangnam branch of Easy Dong-an Clinic is holding a K-beauty and K-medical academy for prospective Chinese medical professionals, spreading Korean medical technology and know-how.
- Huons' HA filler is showing continuous growth in overseas markets including China, and toxins and HA fillers are complementary items, which is increasing China's interest in Korea's beauty treatment technology.
- As the Korean plastic surgery market develops and demand for minor procedures increases, the distribution and delivery market for related products including fillers is growing along with it.
SC Engineering Subsidiary Cellontec Enters Chinese Market
INews24, Go Jong-min reporter
Cellontec is engaged in the bio-collagen business.
Cartizol, a product with enhanced tissue regeneration effects,
in addition to existing symptom relief effects,
accounts for over 50% of the company's bio-collagen sales.
The company aims to expand the global medical and beauty market
by entering the Chinese market.
Currently, the Chinese filler market is saturated with H (hyaluronic acid) products,
but the company believes there is potential for other products.
Easy Dong-an Clinic Gangnam Branch Holds Skin and Plastic Surgery Academy for Prospective Chinese Medical Professionals
Easy Dong-an Clinic Gangnam Branch held its first Easy Dong-an Skin and Plastic Surgery Academy to spread K-beauty and K-Medical to prospective Chinese medical professionals.
Over 100 Chinese prospective medical professionals participated in the academy over four sessions.
The academy is a two-day program, and the curriculum for each day is as follows.
Day 1: Theoretical lectures on representative skin beauty treatments such as Botox, fillers, and thread lifts, case studies of actual procedures, and sharing of treatment know-how.
Day 2: Experience of the Korean medical system and a tour of Easy Dong-an Gangnam Branch, with CEO Dr. Do Jae-woon conducting live demonstrations. After the Day 2 lecture, Dr. Do personally awards certificates to the attendees.
K-beauty has now evolved into K-medical culture.
In the past, it was Korea's beauty market, but now it seems to have expanded to include the beauty (medical) market.
Hugel's HA (Hyaluronic Acid) Filler Sales Surge
Money Today
I'm interested in Hugel.
Hugel's flagship product, 'Botulax,' is the top seller in the domestic market.
It is a key revenue source, being the first domestically produced product to successfully enter the Chinese market.
However, the growth rate has been marginal.
The stagnant sales can be attributed to factors such as the depletion of inventory by the partner company in China and overseas market issues such as the restructuring of European operations.
On the other hand, HA fillers have seen sustained sales growth in countries where they have already entered, such as the UK, France, and Germany. Sales to China have also begun in earnest since obtaining approval in 2022, resulting in a 40% increase in sales year-on-year. In addition, approval was granted in Thailand, the largest beauty and plastic surgery market in Southeast Asia, in July 2023. The company plans to launch its products in Thailand within the year, suggesting further growth potential.
HA fillers are second only to botulinum toxin for Hugel, but in some European countries such as Italy, Spain, and Romania, they have a higher number of procedures than botulinum toxin.
According to the International Society of Aesthetic Plastic Surgery (ISAPS), in 2021, botulinum toxin accounted for 7.31 million procedures and HA fillers for 5.28 million procedures, representing 41.6% and 30.0%, respectively. These two procedures, along with hair removal, are among the top three areas of global aesthetic and plastic surgery procedures, accounting for 82% of the total.
Botulinum toxin and HA fillers are complementary products.
Botulinum toxin temporarily paralyzes the muscles that create wrinkles, while
HA fillers fill in sunken areas of the skin, making them appear fuller and restoring volume.
Kim Jeong-hyeon, a research analyst at Kyobo Securities, said, "Hugel's botulinum toxin sales have slightly increased this year, but the growth rate is showing signs of slowing down."
It's amazing that Hugel is achieving success in China, the world's largest producer of HA.
As Korean plastic surgery has developed, so has the quality of minimally invasive procedures.
It seems that the Chinese are eager to purchase Korea's treatment know-how and accumulated data.
That's why they are opening academies to share this know-how, and the Chinese want to apply it in their own country.
I've been seeing a lot of wholesale and retail distribution of fillers lately.
The number of searches for "Botox" and "Filler" keywords in the Naver cafe Hado-sa has skyrocketed.
Does this mean the market is growing?
This trend suggests that the market for fillers will become even more active, specializing and becoming more specific, with not only wholesale and retail sellers in Southeast Asia and China but also companies involved in the delivery of fillers and botulinum toxin.
M Medi Consumer News
